La Gerche said studies show bradycardia, defined in the study as a heart rate ≤ 40 beats/min, and sinus pauses of 2-3 seconds ...

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the ...

Austin, Texas, United States, January 5th, 2026, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...

HeartBeam, Inc. , a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, ...

Patients with long COVID may demonstrate persistent autonomic dysfunction that is similar to patients with pure autonomic failure when adjusted for age and sex, according to a study published Dec. 10 ...

HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...

The relationship between exercise and cardiovascular (CV) health remains a robust area of investigation, encompassing molecular studies, cohort analyses, and randomized controlled trials. CV ...

HeartBeam’s Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias New study presented at HRX Live 2025 demonstrates continued advancement of company’s AI program ...

New study presented at HRX Live 2025 demonstrates continued advancement of company’s AI program HeartBeam's AI algorithm performed equally well on HeartBeam 3D ECG system and standard 12L ECGs in ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...